MS in Asian countries

International MS Journal

Volumn 13, Issue 2, 2006, Pages 58-65

  Wasay, M ^a   Khatri, I A ^b   Khealani, B ^a   Sheerani, M ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Asia; Literature review; Middle East; Multiple sclerosis; Opticospinal multiple sclerosis

Indexed keywords

HLA ANTIGEN CLASS 2;

ALLELE; ASIA; CLINICAL FEATURE; DISEASE COURSE; GEOGRAPHIC DISTRIBUTION; HUMAN; MEDICAL LITERATURE; MIDDLE EAST; MULTIPLE SCLEROSIS; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; REVIEW;

ADULT; ALLELES; ASIA; HLA-B ANTIGENS; HLA-DR2 ANTIGEN; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; PREVALENCE;

EID: 33646777440     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Kuroiwa Y, Igata A, Itahara K, Koshijima S, Tsubaki T, Toyokura Y et al. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 1975; 25: 845-851.
2. Kuroiwa Y, Hung TP, Landsborough D, Park CS, Singhal BS, Soemargo S et al. Multiple sclerosis in Asia. Neurology 1977; 27: 188-192.
3. Kuroiwa Y. Clinical and epidemiological aspects of multiple sclerosis in Japan. Jpn J Med 1982; 21: 135-140.
4. Kira J, Kanai T, Nishimura Y, Yamasaki K, Matsushita S, Kawano Y et al. Western versus Asian types of multiple sclerosis; immunogenetically and clinically distinct disorders. Ann Neurol 1996; 40: 509-574.
5. Kira J, Yamasaki K, Horiuchi I, Ohyagi Y, Taniwaki T, Kawano Y. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999; 166: 53-57.
6. Houzen H, Niino M, Kikuchi S, Toshiyuki F, Nogoshi S, Matsumoto H et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003; 211: 49-53.
7. Fukazawa T, Tashiro K, Hamada T, Moriwaka F, Matsumoto A, Shima K et al. Multiple sclerosis in Hokkaido, the northernmost island of Japan: prospective analyses of clinical features. Intern Med 1992; 31: 349-352.
8. Hou JB, Zhang ZX. Prevalence of multiple sclerosis: A door-to-door survey in Lan Cang La Hu Zu Autonomous County, Yunnan Province of China. Neuroepidemiology 1992; 11: 52.
9. Zhao BX, Liu XQ, Guo YP, Yang YC, Huang HF. Multiple Sclerosis. A clinical study of 70 cases. Eur Neurol 1981; 20: 394-400.
10. Lau KK, Wong LKS, Li LS, Chan YW, Li HL, Wong Y. Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J 2002; 8: 77-80.
11. Yu YL, Woo E, Hawkins BR, Ho HC, Huang CY. Multiple sclerosis amongst Chinese in Hong Kong. Brain 1989; 112: 1445-1467.
12. Lau KK, Lee PO, Chan KY, Chan YW, Chin KF. Interferon treatment for multiple sclerosis patients in Hong Kong. Hong Kong Med J 2000; 6: 221-223.
13. Hung TP, Landsborough D, Hsi MS. Multiple sclerosis amongst Chinese in Taiwan. J Neurol Sci 1970; 27: 459-484.
14. Das A, Puvanendran K. A retrospective review of patients with clinically definite multiple sclerosis. Ann Acad Med Singapore 1998; 27: 204-209.
15. Jitpimolmard S, Vejjajiva A. Clinical features and clinical course of multiple sclerosis in Thai patients: a report of 50 cases. J Med Assoc Thai 1994; 77: 239-243.
16. Chiemchanya S, Visudhiphan P. Multiple sclerosis in children; a report of 17 Thai pediatric patients. J Med Assoc Thai 1993; 76: 28-33.
17. Kurtzke JF, Park CS, Oh SJ. Multiple sclerosis in Korea. Clinical features and prevalence. J Neurol Sci 1968; 6: 463-481.
18. Tan CT. Multiple sclerosis in Malaysia. Arch Neurol 1988; 45: 624-027.
19. Onodera H, Nakashima I, Fujihara K, Nagata T, Itoyama Y. Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis. Tohoku J Exp Med 1999; 189: 259-265.
20. Kalanie H, Gharagozli K, Kolonie AR. Multiple sclerosis: report on 200 cases from Iran. Mult Scler 2003; 9: 36-38.
21. Gangopadhyay G, Das SK, Sarda P, Saha SP, Gangopadhyay PK, Roy TN et al. Clinical profile of multiple sclerosis in Bengal. Neurol India 1999; 47: 18-21.
22. Kurtzke JF, Wallin MT: Neuroepidemiology. In: Neurology in Clinical Practice: Principles of Diagnosis and Management (Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds). Boston: Butterworth-Heinemann 2000; pp759-776.
23. Singhal BS. Multiple sclerosis. Neurol India 1999; 47: 1-2.
24. Siddiqui I, Aleem S, Kayani N, Baig S. CSF oligoclonal bands in multiple sclerosis. J Pak Med Assoc 2002; 52: 351-353.
25. Senanayake B, Ranawaka U, Wijesekara J. Multiple sclerosis in Sri Lanka. Ceylon Med J 2001; 46: 159-100.
26. Kalanie H, Kamgooyan M, Sadeghian H, Kalanie AR. Histocompatibility antigen (HLA) with multiple sclerosis in Iran. Mult Scler 2000; 6: 317-319.
27. Jain S, Moheshwari MC. Multiple sclerosis: Indian experience in the last thirty years. Neuroepidemiology 1985; 4: 96-107.
28. Syal P, Prabhakar S, Thussu A, Seghal S, Khandelwal N. Clinical profile of multiple sclerosis in north-west India. Neural India 1999; 47: 12-17.
29. Mani J, Chaudhary N, Ravat S, Shah PU. Multiple sclerosis: Experience in neuroimaging era from western India. Neurol India 1999; 47: 8-11.
30. Bansil S, Singhal BS, Ahuja GK, Ladiwala U, Behari M, Friede R et al. Comparison between multiple sclerosis in India and United States: a case-control study. Neurology 1990; 46: 385-387.
31. Bharucha NE, Bharucha EP, Wadia NH, Singhal BS, Bharucha AE, Bhise AV et al. Prevalence of multiple sclerosis in the Parsis of Bombay. Neurology 1988; 38: 727-729.
32. Wadia NH, Bhatia K. Multiple sclerosis is prevalent in the Zoroastrians (Parsis) of India. Ann Neurol 1990; 28: 177-179.
33. Wadia NH, Trikannad VS, Krishnaswamy PR. Association of HLA-B12 with multiple sclerosis in India. Tissue Antigens 1980; 15: 90-93.
34. Wadia NH, Trikannad VS, Krishnaswamy PR. HLA antigens in multiple sclerosis amongst Indians. J Neurol Neurosurg Psychiatry 1981; 44: 849-851.
35. Razdan S, Kaul RL, Motta A, Kaul S, Bhatt RK. Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986. Neuroepidemiology 1994; 13: 113-119.
36. Olek MS, Dawson DM. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Neurology in Clinical Practice; Principles of Diagnosis and Management (Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds). Boston: Butterworth Heinemann, 2000; pp1431-1466.
37. Bansil S, Singhal BS, Ahuja GK, Riise T, Ladiwala U, Behari M et al. Multiple sclerosis in India: a case control study of environmental exposures. Acta Neurol Scand 1997; 95: 90-95.
38. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 1975; 51: 110-157.
39. Al-Din AS, Khogali M, Poser CM, Al-Nassar KE, Shakir R, Hussain J et al. Epidemiology of multiple sclerosis in Arabs in Kuwait: a comparative study between Kuwaitis and Palestinians. J Neurol Sci 1990; 100: 137-141.
40. Al-Din AS. Multiple sclerosis in Kuwait: clinical and epidemiological study. J Neurol Neurosurg Psychiatry 1986; 49: 928-931.
41. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51: 705-772.
42. Al-Din AS, El-Khateeb M, Kurdi A, Mubaidin A, Wriekat A, Al-Shehab A et al. Multiple sclerosis in Arabs in Jordan. J Neurol Sci 1995; 131: 144-149.
43. Hamdi TI. Multiple sclerosis in Iraq: a clinical and geomedical survey. J Postgr Med 1975; 21: 1-9.
44. Al-Araji A, Mohammed AI. Multiple sclerosis in Iraq: does it have the same features encountered in Western countries? J Neurol Sci 2005; 234: 47-71.
45. Kurtzke JF. Multiple sclerosis in time and space - geographic clues to cause. J Neurovirol 2000; 6: S134-5140.
46. Kwon OJ, Karni A, Israel S, Brautbar C, Amar A, Meiner Z et al. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol 1999; 56: 555-560.
47. Karni A, Kahana E, Zilber N, Abramsky O, Alter M, Karussis D. The frequency of multiple sclerosis in Jewish and Arab populations in greater Jerusalem. Neuroepidemiology 2003; 22: 82-86.
48. al Rajeh S, Bademosi O, Ismail H, Awada A, Dawodu A, al-Freihi H et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology 1993; 12: 164-178.
49. Daif AK, Al-Rajeh S, Awada A, Al Bunyan M, Ogunniyi A, Abduljabar M et al. Pattern of presentation of multiple sclerosis in Saudi Arabia: analysis based on clinical and paraclinical features. Eur Neurol 1998; 39: 182-186.
50. Yaqub BA, Daif AK. Multiple sclerosis in Saudi Arabia. Neurology 1988; 38: 621-623.
51. Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 2003; 61: 238-240.
52. Pulatov AM. Determinant factor and pathogenesis of multiple sclerosis. Zh Nevropatol Psikhiatr Im S S Korsakova 1979; 79: 142-147.
53. Alaev BA, Umanskii KG, Samibaev MKh. Clinical picture and course of multiple sclerosis among inhabitants of southwest regions of Uzbekistan. Zh Nevropatol Psikhiatr Im S S Korsakova 1985; 85: 210-214
54. Alaev BA. Ethnic factors and their relation to the pathogenesis and geography of multiple sclerosis. Zh Nevropatol Psikhiatr Im S S Korsakova 1992; 92: 9-12
55. Alaev BA, Aslanov AM. Climatic factors and clinical polymorphism of multiple sclerosis. Zh Nevropatol Psikhiatr Im S S Korsakova 1990; 90: 9-12.
56. Murray S, Bashir K, Penrice G, Womersley SJ. Epidemiology of multiple sclerosis in Glasgow. Scott Med J 2004; 49: 100-104.
57. Dean G, Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 565-568.
58. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2: 117-127.
59. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004; 63: 2039-2045.
60. Chan KH, Tsang KL, Fong GC, Cheung RT, Ho SL. Idiopathic severe recurrent transverse myelitis: a restricted variant of neuromyelitis optica. Clin Neurol Neurosurg 2005; 107: 132-135.
61. Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E et al. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol 2004; 251: 47-52.
62. de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003; 9: 521-525.
63. de Seze J, Stojkovic T, Ferriby D, Gauvrit JY, Montagne C, Mounier-Vehier F et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002; 197: 57-61.
64. Fujihara K, Nakashima I, Itoyama Y. Optic-spinal form of multiple sclerosis and immune-mediated myelopathy in Japan. J Neural Transm Suppl 2000; 58: 205-214.
65. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
66. Ono T, Zambenedetti MR, Yamasaki K, Kawano Y, Kamikawaji N, Ito H et al. Molecular analysis of HLA class I (HLA-A and-B) and HLA class II [HLA-DRB1) genes in Japanese patients with multiple sclerosis {Western type and Asian type). Tissue Antigens 1998; 52: 539-542.
67. Kira J, Kanai T, Nishimura Y, Yamasaki K, Matsushita S, Kawano Y et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996; 40: 569-574.
68. Haase CG. Devics neuromyelitis optica. Disease or variants of multiple sclerosis? Nervenarzt 2001; 72: 750-754.
69. Wu XM, Osoegawa M, Yamasaki K, Kawano Y, Ochi H, Horiuchi I et al. Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperlgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci 2000; 177: 24-31.
70. Weinshenker B. Western vs optic-spinal MS: two diseases, one treatment? Neurology 2005; 64: 594-595.
71. Weinshenker BG, Fujihara K, Pittock SJ. The Asian optic-spinal form of MS is the same entity as neuromyelitis optica in Caucasians: insights from a novel serum marker. Neurology 2004; 62 (Suppl 5): A 480. Abstract P06.061.
72. Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005; 64: 621-630.
73. Fujihara K, Ong BK. MS across continents: challenging our knowledge of MS in Asia and the Middle East. Report from the 2nd MS Forum Pan-Asian Conference, 19-20 November 2004, Ho Chi Minh City, Vietnam. Int MS J 2005; 12: 34-35.